Clinical Trial Update: A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing the immunogenicity and safety of Quinvaxem vaccine given in mono-dose vials versus Uniject.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• Quinvaxem (Diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: Crucell Holland BV | Conditions: Diphtheria, Pertussis | Phase 3 | Status: COMPLETED